Using the RIP-NINJA mouse model to study how PD-1 regulation in the pancreas prevents autoimmune induction and checkpoint therapy-induced diabetes.
Using DIPS, a non-invasive skin sampling technique, to build cytokine-based biomarker panels that predict biologic treatment response in psoriasis and atopic dermatitis.
Investigating how copper transport via SLC31A1 regulates pro-inflammatory Th17 cell activity, this project uncovers a novel link between immune cell metabolism and MS, pointing toward new therapeutic targets.
Repurposing topical MC903, an FDA-approved vitamin D analog, to trigger skin-derived bile acid synthesis and generate systemic anti-inflammatory effects in lupus nephritis.
Developing 10E5-1, an anti-activin A antibody delivered via mRNA-LNP, to suppress pathogenic antibody production and treat rheumatoid arthritis through a novel mechanism.
Developing VCAM-1-targeted lipid nanoparticles delivering IL-10 mRNA to reduce neuroinflammation and improve outcomes after intracerebral hemorrhage.
Building a spatial single-cell atlas of healthy and diseased human kidneys to redefine immune-mediated kidney disease and identify precision diagnostic and therapeutic targets.
Uncovering the mechanisms by which inflammasomes drive aberrant inflammation in humans to identify new therapeutic targets for autoinflammatory diseases and sepsis.
You might also be interested in… Soluble urine activated leukocyte cell adhesion molecule is a strong predictor of lupus nephritis Rheumatology Chu, D; Schwartz, N; Ampudia, J; Guthridge, J; James, […]
